Moderna, Inc. DEF 14A Filing

Ticker: MRNA · Form: DEF 14A · Filed: 2024-03-21T00:00:00.000Z

Sentiment: neutral

Topics: Moderna, MRNA, DEF 14A, SEC Filing, Executive Compensation

TL;DR

<b>Moderna, Inc. filed its DEF 14A with the SEC on March 21, 2024, detailing executive compensation and corporate information.</b>

AI Summary

Moderna, Inc. (MRNA) filed a Proxy Statement (DEF 14A) with the SEC on March 21, 2024. Moderna, Inc. filed a DEF 14A with the SEC on March 21, 2024. The filing covers the period ending May 6, 2024. The company's principal executive offices are located at 200 Technology Square, Cambridge, MA. Moderna was formerly known as Moderna Therapeutics, Inc., with a name change on August 22, 2016. The filing includes detailed executive compensation data for PEO and Non-PEO members for fiscal years 2020-2023.

Why It Matters

For investors and stakeholders tracking Moderna, Inc., this filing contains several important signals. This filing provides crucial information about executive compensation packages, which can influence investor perception and executive retention. The DEF 14A filing is a key document for shareholders to understand the company's governance and how executive pay is structured.

Risk Assessment

Risk Level: — Moderna, Inc. shows moderate risk based on this filing. The filing is a routine DEF 14A, providing standard corporate disclosures without immediate financial or operational red flags.

Analyst Insight

Review the executive compensation details to understand pay structures and potential impacts on shareholder value.

Key Numbers

2024-03-21 — Filing Date (DEF 14A filing date)
2024-05-06 — Period of Report (Conformed period of report)
2016-08-22 — Name Change Date (Date of former company name change)

Key Players & Entities

Moderna, Inc. (company) — Filer
Moderna Therapeutics, Inc. (company) — Former company name
200 Technology Square, Cambridge, MA (company) — Business address

FAQ

When did Moderna, Inc. file this DEF 14A?

Moderna, Inc. filed this Proxy Statement (DEF 14A) with the SEC on March 21, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Moderna, Inc. (MRNA).

Where can I read the original DEF 14A filing from Moderna, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Moderna, Inc..

What are the key takeaways from Moderna, Inc.'s DEF 14A?

Moderna, Inc. filed this DEF 14A on March 21, 2024. Key takeaways: Moderna, Inc. filed a DEF 14A with the SEC on March 21, 2024.. The filing covers the period ending May 6, 2024.. The company's principal executive offices are located at 200 Technology Square, Cambridge, MA..

Is Moderna, Inc. a risky investment based on this filing?

Based on this DEF 14A, Moderna, Inc. presents a moderate-risk profile. The filing is a routine DEF 14A, providing standard corporate disclosures without immediate financial or operational red flags.

What should investors do after reading Moderna, Inc.'s DEF 14A?

Review the executive compensation details to understand pay structures and potential impacts on shareholder value. The overall sentiment from this filing is neutral.

How does Moderna, Inc. compare to its industry peers?

Moderna operates in the biotechnology sector, focusing on mRNA therapeutics and vaccines.

Are there regulatory concerns for Moderna, Inc.?

The filing is made under the Securities Exchange Act of 1934, requiring public companies to disclose material information to shareholders.

Industry Context

Moderna operates in the biotechnology sector, focusing on mRNA therapeutics and vaccines.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, requiring public companies to disclose material information to shareholders.

What Investors Should Do

Analyze the executive compensation table for key executives.
Note any changes in corporate governance disclosures.
Verify the period of report and filing date for accuracy.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a proxy statement typically filed annually to provide information to shareholders for voting purposes. Specific comparative data from a previous filing is not directly available in this snippet.

From the Filing

0001308179-24-000208.txt : 20240321 0001308179-24-000208.hdr.sgml : 20240321 20240321084638 ACCESSION NUMBER: 0001308179-24-000208 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 98 CONFORMED PERIOD OF REPORT: 20240506 FILED AS OF DATE: 20240321 DATE AS OF CHANGE: 20240321 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 24769617 BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 DEF 14A 1 lmrna2024_def14a.htm MODERNA, INC. - DEF 14A false 0001682852 DEF 14A 0001682852 2023-01-01 2023-12-31 0001682852 2022-01-01 2022-12-31 0001682852 2021-01-01 2021-12-31 0001682852 2020-01-01 2020-12-31 0001682852 ecd:PeoMember mrna:DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember 2023-01-01 2023-12-31 0001682852 ecd:NonPeoNeoMember mrna:DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember 2023-01-01 2023-12-31 0001682852 ecd:PeoMember mrna:DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember 2022-01-01 2022-12-31 0001682852 ecd:NonPeoNeoMember mrna:DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember 2022-01-01 2022-12-31 0001682852 ecd:PeoMember mrna:DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember 2021-01-01 2021-12-31 0001682852 ecd:NonPeoNeoMember mrna:DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember 2021-01-01 2021-12-31 0001682852 ecd:PeoMember mrna:DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember 2020-01-01 2020-12-31 0001682852 ecd:NonPeoNeoMember mrna:DeductionForAmountsReportedUnderTheStockAwardsAndOptionAwardsColumnsOfTheSummaryCompensationTableMember 2020-01-01 2020-12-31 0001682852 ecd:PeoMember mrna:IncreaseDecreaseForTheInclusionOfRule402vEquityValuesMember 2023-01-01 2023-12-31 0001682852 ecd:NonPeoNeoMember mrna:IncreaseDecreaseForTheInclusionOfRule402vEquityValuesMember 2023-01-01 2023-12-31 0001682852 ecd:PeoMember mrna:IncreaseDecreaseForTheInclusionOfRule402vEquityValuesMember 2022-01-01 2022-12-31 0001682852 ecd:NonPeoNeoMember mrna:IncreaseDecreaseForTheInclusionOfRule402vEquityValuesMember 2022-01-01 2022-12-31 0001682852 ecd:PeoMember mrna:IncreaseDecreaseForTheInclusionOfRule402vEquityValuesMember 2021-01-01 2021-12-31 0001682852 ecd:NonPeoNeoMember mrna:IncreaseDecreaseForTheInclusionOfRule402vEquityValuesMember 2021-01-01 2021-12-31 0001682852 ecd:PeoMember mrna:IncreaseDecreaseForTheInclusionOfRule402vEquityValuesMember 2020-01-01 2020-12-31 0001682852 ecd:NonPeoNeoMember mrna:IncreaseDecreaseForTheInclusionOfRule402vEquityValuesMember 2020-01-01 2020-12-31 0001682852 ecd:PeoMember mrna:YearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember 2023-01-01 2023-12-31 0001682852 ecd:NonPeoNeoMember mrna:YearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember 2023-01-01 2023-12-31 0001682852 ecd:PeoMember mrna:YearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember 2022-01-01 2022-12-31 0001682852 ecd:NonPeoNeoMember mrna:YearEndFairValueOfEquityAwardsGrantedDuringYearThatRemainedUnvestedAsOfLastDayOfYearMember 2022-01-01 2022-12-31 0001682852 ecd:PeoMember mrna:YearEndFairValueOf